Comparing Caribou Biosciences (NASDAQ:CRBU) and HCW Biologics (NASDAQ:HCWB)

Caribou Biosciences (NASDAQ:CRBU) and HCW Biologics (NASDAQ:HCWB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.

Insider and Institutional Ownership

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 9.1% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Caribou Biosciences and HCW Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,085.00%	-102.74%	-69.45%
HCW Biologics	-83.03%	-262.33%	-34.90%

Earnings and Valuation

This table compares Caribou Biosciences and HCW Biologics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$9.44 million	4.24	-$148.12 million	($1.03)	-0.36
HCW Biologics	$6.72 million	0.29	-$7.96 million	($27.60)	-0.03

HCW Biologics has lower revenue, but higher earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Caribou Biosciences and HCW Biologics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1	4	1	1	2.29
HCW Biologics	1	0	1	0	2.00

Caribou Biosciences currently has a consensus target price of $4.50, suggesting a potential upside of 1,112.94%. HCW Biologics has a consensus target price of $30.00, suggesting a potential upside of 3,293.67%. Given HCW Biologics’ higher probable upside, analysts clearly believe HCW Biologics is more favorable than Caribou Biosciences.

Volatility & Risk

Caribou Biosciences has a beta of 2.5, indicating that its share price is 150% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500.

Summary

Caribou Biosciences beats HCW Biologics on 8 of the 14 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc. is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses CRISPR gene-editing technology to engineer allogeneic, or “off-the-shelf,” immune-cell therapies designed to target cancer cells while reducing limitations associated with individualized cell treatments. Caribou’s research platform is based on CRISPR hybrid RNA-DNA guide technology, which is intended to support precise and efficient genome editing.

About HCW Biologics

HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression. HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression.